GlassScriptPhysician profile
Darren R Machak
NPI 1447487996
$2,558.80
in general payments reported to CMS, 2019-2025
29 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $223 · 2021: $248 · 2022: $431 · 2023: $293 · 2024: $166 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $832.03 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $787.64 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $420.09 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $183.25 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.78 | 2022-2025 | |
| Grifols USA, LLC | $102.58 | 2019-2023 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.01 | 2019-2021 | |
| Abbvie INC. | $89.76 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $75.10 | 2019-2021 | |
| Lilly USA, LLC | $66.37 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $62.50 | 2019-2023 | Bexsero, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $56.83 | 2019-2021 | |
| Astellas Pharma US INC | $54.85 | 2019-2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $46.67 | 2019 | |
| Daiichi Sankyo INC. | $42.69 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $37.08 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $35.98 | 2025 | Repatha, Otezla |
| Allergan, INC. | $35.71 | 2019-2020 | |
| Boston Scientific Corporation | $31.57 | 2023 | Watchman Flx |
| Sanofi Pasteur INC. | $27.63 | 2019-2020 | |
| Edwards Lifesciences Corporation | $22.47 | 2023 | |
| Ucb, INC. | $21.99 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $20.98 | 2024 | Airsupra |
| Shield Therapeutics INC | $19.82 | 2025 | |
| Scilex Pharmaceuticals INC. | $16.88 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.51 | 2023 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $15.14 | 2023 | |
| Phathom Pharmaceuticals, INC. | $14.57 | 2024 | Voquezna |
| Amarin Pharma, INC. | $13.29 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.06 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darren Machak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.